HUE053229T2 - FK506 alkalmazása pulmonális artériás hipertenzió kezelésére - Google Patents

FK506 alkalmazása pulmonális artériás hipertenzió kezelésére

Info

Publication number
HUE053229T2
HUE053229T2 HUE12779354A HUE12779354A HUE053229T2 HU E053229 T2 HUE053229 T2 HU E053229T2 HU E12779354 A HUE12779354 A HU E12779354A HU E12779354 A HUE12779354 A HU E12779354A HU E053229 T2 HUE053229 T2 HU E053229T2
Authority
HU
Hungary
Prior art keywords
treatment
arterial hypertension
pulmonary arterial
pulmonary
hypertension
Prior art date
Application number
HUE12779354A
Other languages
English (en)
Hungarian (hu)
Inventor
Edda Spiekerkoetter
Marlene Rabinovitch
Philip Beachy
David Solow-Cordero
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of HUE053229T2 publication Critical patent/HUE053229T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE12779354A 2011-05-02 2012-04-30 FK506 alkalmazása pulmonális artériás hipertenzió kezelésére HUE053229T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161481317P 2011-05-02 2011-05-02

Publications (1)

Publication Number Publication Date
HUE053229T2 true HUE053229T2 (hu) 2021-06-28

Family

ID=47108011

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12779354A HUE053229T2 (hu) 2011-05-02 2012-04-30 FK506 alkalmazása pulmonális artériás hipertenzió kezelésére

Country Status (19)

Country Link
US (6) US9474745B2 (enExample)
EP (3) EP4279130A3 (enExample)
JP (1) JP6177765B2 (enExample)
AU (2) AU2012250974B9 (enExample)
CA (1) CA2834368C (enExample)
CY (1) CY1123900T1 (enExample)
DK (2) DK2704711T3 (enExample)
ES (2) ES2856173T3 (enExample)
FI (1) FI3821891T3 (enExample)
HR (1) HRP20210245T1 (enExample)
HU (1) HUE053229T2 (enExample)
LT (1) LT2704711T (enExample)
PL (1) PL2704711T3 (enExample)
PT (2) PT3821891T (enExample)
RS (1) RS61480B1 (enExample)
SI (1) SI2704711T1 (enExample)
SM (1) SMT202100085T1 (enExample)
WO (1) WO2012151153A1 (enExample)
ZA (1) ZA201307905B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
MX2017014301A (es) * 2015-05-08 2018-03-23 Vivus Inc Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.
CN108070566A (zh) * 2015-08-05 2018-05-25 中国医学科学院基础医学研究所 肺动脉高压治疗药物的干细胞筛选模型及应用
ES2683921B1 (es) * 2017-03-28 2019-04-22 Univ Vigo Método para la determinación del pronóstico en sujetos diagnosticados con hipertensión arterial pulmonar
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University ENZASTAURIN AND FRAGILE HISTIDINTRIAD (FHIT) - ENHANCING AGENTS FOR TREATMENT OF PULMONAL HYPERTENSION
EP3773571A1 (en) 2018-03-28 2021-02-17 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Prevention or treatment of chronic organ injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
FR2936060B1 (fr) * 2008-09-17 2010-11-19 Assist Publ Hopitaux De Paris Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
DK2704711T3 (da) 2011-05-02 2021-02-22 Univ Leland Stanford Junior Anvendelse af fk506 til behandlingen af pulmonal arteriel hypertension

Also Published As

Publication number Publication date
SMT202100085T1 (it) 2021-05-07
CA2834368C (en) 2020-02-18
ES2856173T3 (es) 2021-09-27
WO2012151153A1 (en) 2012-11-08
EP4279130A2 (en) 2023-11-22
LT2704711T (lt) 2021-04-26
EP2704711A4 (en) 2014-11-19
JP2014513121A (ja) 2014-05-29
US9474745B2 (en) 2016-10-25
EP3821891A1 (en) 2021-05-19
DK2704711T3 (da) 2021-02-22
CA2834368A1 (en) 2012-11-08
HRP20210245T1 (hr) 2021-04-02
AU2012250974B2 (en) 2017-05-04
US20170007585A1 (en) 2017-01-12
ZA201307905B (en) 2015-05-27
US20180185340A1 (en) 2018-07-05
US20220184042A1 (en) 2022-06-16
CY1123900T1 (el) 2022-05-27
EP3821891B1 (en) 2023-06-07
JP6177765B2 (ja) 2017-08-09
US20140135358A1 (en) 2014-05-15
ES2954905T3 (es) 2023-11-27
US12521379B2 (en) 2026-01-13
SI2704711T1 (sl) 2021-04-30
PL2704711T3 (pl) 2021-07-05
US20230404982A1 (en) 2023-12-21
AU2017210583A1 (en) 2017-08-24
DK3821891T3 (da) 2023-09-04
FI3821891T3 (fi) 2023-08-24
AU2012250974A1 (en) 2013-11-14
AU2017210583B2 (en) 2019-02-07
PT3821891T (pt) 2023-08-31
EP2704711B1 (en) 2020-12-02
US20190091208A1 (en) 2019-03-28
AU2012250974B9 (en) 2017-05-18
RS61480B1 (sr) 2021-03-31
EP2704711A1 (en) 2014-03-12
EP4279130A3 (en) 2024-02-21
PT2704711T (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
IL231228A0 (en) Bicyclic heterocycle derivatives for the treatmen t of pulmonary arterial hypertension
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3646824T3 (da) Kateterbaseret hjerteklapprotese
DK2734126T3 (da) Medicinske anordninger med aftagelige drejelige kæber
DK2539015T3 (da) Nethindeprotese
IL229582B (en) Anti-kir antibodies for the treatment of inflammatory disorders
IL237021B (en) Pharmaceutical composition for treatment of pulmonary arterial hypertension with mesenchymal stem cells
DK3011936T3 (da) Vævsmanipulerede konstrukter
IL229017B (en) Oxidative retinal diseases
PT2552438T (pt) Métodos de tratamento de carcinoma hepatocelular
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
IL231092A0 (en) Treatment of rhinitis
EP2774585A4 (en) Stent
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
CO6870004A2 (es) Métodos de modulación de un microarn en el tratamiento de la hipertensión arterial pulmonar
EP2783256A4 (en) Therapeutic eyewear
IL234606B (en) Novel methods and composition for treatment of disease
ZA201307905B (en) Use of fk506 for the treatment of pulmonary arterial hypertension
DK2673363T3 (da) Behandling af angiogenesesygdomme
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
DK2590565T3 (da) Blodprøvetagning
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
IL227814A0 (en) Cathepsin c inhibitors